|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
JP6976241B2
(ja)
*
|
2015-08-14 |
2021-12-08 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗ｔｉｇｉｔ抗体
|
|
MX389710B
(es)
|
2016-05-27 |
2025-03-20 |
Agenus Inc |
Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
CA3032897A1
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
|
KR102576042B1
(ko)
|
2016-10-11 |
2023-09-07 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
CA3044664C
(en)
|
2016-11-30 |
2022-11-22 |
Oncomed Pharmaceuticals, Inc. |
Methods for treatment of cancer comprising tigit-binding agents
|
|
JP2020510422A
(ja)
*
|
2017-02-28 |
2020-04-09 |
シアトル ジェネティックス， インコーポレイテッド |
抗ｔｉｇｉｔ抗体
|
|
RS64576B1
(sr)
*
|
2017-05-01 |
2023-10-31 |
Agenus Inc |
Anti-tigit antitela i postupci njihove primene
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
RU2019138507A
(ru)
|
2017-05-02 |
2021-06-02 |
Мерк Шарп И Доум Корп. |
Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
|
|
MX2019014265A
(es)
|
2017-06-01 |
2020-08-03 |
Compugen Ltd |
Tratamientos conjuntos triples con anticuerpos.
|
|
WO2018229163A1
(en)
|
2017-06-14 |
2018-12-20 |
King's College London |
Methods of activating v delta 2 negative gamma delta t cells
|
|
GB201709808D0
(en)
*
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
IL272227B2
(en)
*
|
2017-07-27 |
2025-09-01 |
iTeos Belgium SA |
Anti-tigit antibodies
|
|
US11512129B2
(en)
|
2017-09-29 |
2022-11-29 |
Jiangsu Hengrui Medicine Co., Ltd. |
TIGIT antibody, antigen-binding fragment thereof, and medical use thereof
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
TWI816729B
(zh)
*
|
2017-12-30 |
2023-10-01 |
英屬開曼群島商百濟神州有限公司 |
抗tigit抗體及其作為治療和診斷的用途
|
|
CN110352200B
(zh)
|
2018-02-06 |
2020-12-11 |
天境生物科技(上海)有限公司 |
抗具有Ig和ITIM结构域的T细胞免疫受体(TIGIT)的抗体及其应用
|
|
KR102825164B1
(ko)
|
2018-03-27 |
2025-06-26 |
브리스톨-마이어스 스큅 컴퍼니 |
자외선 신호를 사용한 단백질 농도의 실시간 모니터링
|
|
BR112021001201A2
(pt)
*
|
2018-07-25 |
2021-04-27 |
Innovent Biologics (Suzhou) Co., Ltd. |
anticorpo anti-tigit e uso do mesmo
|
|
BR112021003156A2
(pt)
*
|
2018-08-23 |
2021-05-11 |
Seagen, Inc. |
composição, anticorpo que se liga ao tigit humano, formulação farmacêutica, polinucleotídeo isolado, vetor, célula hospedeira, métodos para a produção de um anticorpo que se liga ao tigit humano e de anticorpos afucosilados que se ligam a tigit e para o tratamento de um câncer, e, kit.
|
|
CN109384846B
(zh)
*
|
2018-09-25 |
2020-03-03 |
合肥瑞达免疫药物研究所有限公司 |
能够结合tigit的抗体或其抗原结合片段及用途
|
|
CN113056482A
(zh)
|
2018-10-18 |
2021-06-29 |
默沙东公司 |
抗rsv抗体的制剂及其使用方法
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
KR20210089215A
(ko)
|
2018-11-07 |
2021-07-15 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항-pd-1 항체의 공동-제제
|
|
CN113614109A
(zh)
|
2018-12-21 |
2021-11-05 |
Ose免疫疗法公司 |
双功能抗pd-1/il-7分子
|
|
KR20210113282A
(ko)
|
2019-01-07 |
2021-09-15 |
아이테오스 벨지움 에스에이 |
항-tigit 항체
|
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
|
US20220135619A1
(en)
|
2019-02-24 |
2022-05-05 |
Bristol-Myers Squibb Company |
Methods of isolating a protein
|
|
CN109734806B
(zh)
*
|
2019-03-15 |
2022-07-01 |
安徽安科生物工程（集团）股份有限公司 |
一种全人源抗huTIGIT单克隆抗体及其应用
|
|
JP7645198B2
(ja)
|
2019-05-23 |
2025-03-13 |
ブリストル－マイヤーズ スクイブ カンパニー |
細胞培養培地をモニターする方法
|
|
WO2021008523A1
(zh)
*
|
2019-07-15 |
2021-01-21 |
上海君实生物医药科技股份有限公司 |
抗tigit抗体及其应用
|
|
CN114206929B
(zh)
|
2019-09-03 |
2023-12-22 |
百奥泰生物制药股份有限公司 |
一种抗tigit免疫抑制剂及应用
|
|
WO2021092196A1
(en)
*
|
2019-11-05 |
2021-05-14 |
Merck Patent Gmbh |
Anti-tigit antibodies and uses thereof
|
|
BR112022009405A2
(pt)
*
|
2019-11-15 |
2022-08-09 |
Surface Oncology Inc |
Composições e métodos para imunoterapia
|
|
AU2020406083A1
(en)
|
2019-12-17 |
2022-06-16 |
Boehringer Ingelheim International Gmbh |
Bifunctional molecules comprising an IL-7 variant
|
|
CA3161733A1
(en)
|
2020-01-07 |
2021-05-15 |
Everett Stone |
Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
|
|
EP4094777A4
(en)
*
|
2020-01-21 |
2024-01-24 |
Innovent Biologics (Suzhou) Co., Ltd. |
RECOMBINANT FULLY HUMAN MONOCLONAL ANTI-TIGITE ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
|
|
US20230069749A1
(en)
|
2020-01-29 |
2023-03-02 |
Board Of Regents, The University Of Texas System |
Use of poziotinib for the treatment of cancers with nrg1 fusions
|
|
WO2021155113A1
(en)
|
2020-01-29 |
2021-08-05 |
Board Of Regents, The University Of Texas System |
Use of egfr/her2 tyrosine kinase inhibitors and/or her2/her3 antibodies for the treatment of cancers with nrg1 fusions
|
|
WO2021178814A1
(en)
*
|
2020-03-06 |
2021-09-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-gitr antibodies and uses thereof
|
|
KR20220154140A
(ko)
|
2020-03-13 |
2022-11-21 |
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 |
Pvrig 결합 단백질 및 이의 의학적 용도
|
|
CA3176497A1
(en)
|
2020-05-07 |
2021-11-11 |
Fatima MECHTA-GRIGORIOU |
Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy
|
|
CN114507284B
(zh)
*
|
2020-05-09 |
2023-05-26 |
华博生物医药技术（上海）有限公司 |
抗tigit的抗体、其制备方法和应用
|
|
CN115916348A
(zh)
|
2020-06-18 |
2023-04-04 |
基因泰克公司 |
使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
|
|
WO2021258337A1
(en)
*
|
2020-06-24 |
2021-12-30 |
Huahui Health Ltd. |
Human monoclonal antibodies against tigit for immune related diseases
|
|
TW202216778A
(zh)
|
2020-07-15 |
2022-05-01 |
美商安進公司 |
Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
|
|
WO2022044010A1
(en)
|
2020-08-26 |
2022-03-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections
|
|
WO2022076318A1
(en)
|
2020-10-05 |
2022-04-14 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
|
EP4238991A4
(en)
*
|
2020-11-23 |
2024-05-15 |
Guangdong Fapon Biopharma Inc. |
ANTI-TIGIT ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF
|
|
WO2022112198A1
(en)
|
2020-11-24 |
2022-06-02 |
Worldwide Innovative Network |
Method to select the optimal immune checkpoint therapies
|
|
WO2022124864A1
(ko)
*
|
2020-12-10 |
2022-06-16 |
주식회사 유틸렉스 |
항-tigit 항체 및 이의 용도
|
|
WO2022148781A1
(en)
|
2021-01-05 |
2022-07-14 |
Institut Curie |
Combination of mcoln activators and immune checkpoint inhibitors
|
|
WO2022214653A1
(en)
|
2021-04-09 |
2022-10-13 |
Ose Immunotherapeutics |
New scaffold for bifunctional molecules with improved properties
|
|
US20240182572A1
(en)
|
2021-04-09 |
2024-06-06 |
Ose Immunotherapeutics |
Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
|
|
TW202304965A
(zh)
|
2021-05-04 |
2023-02-01 |
美商艾吉納斯公司 |
抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法
|
|
AU2022272586A1
(en)
|
2021-05-10 |
2024-01-04 |
Medimabbio Inc. |
Anti-tigit antibodies and use thereof
|
|
US20250270315A1
(en)
*
|
2021-07-28 |
2025-08-28 |
Elpiscience (Suzhou) Biopharma, Ltd. |
Novel anti-sirpa antibodies
|
|
TW202320848A
(zh)
|
2021-07-28 |
2023-06-01 |
美商建南德克公司 |
治療癌症之方法及組成物
|
|
JP2024535768A
(ja)
|
2021-09-15 |
2024-10-02 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗ｐｖｒｉｇ／ｔｉｇｉｔ二重特異性抗体を含む医薬組成物
|
|
CN117940453A
(zh)
|
2021-09-15 |
2024-04-26 |
江苏恒瑞医药股份有限公司 |
特异性结合pd-1的蛋白及其医药用途
|
|
WO2023056361A1
(en)
|
2021-09-29 |
2023-04-06 |
Board Of Regents, The University Of Texas System |
Anti-hsp70 antibodies and therapeutic uses thereof
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
CN118591557A
(zh)
*
|
2022-01-24 |
2024-09-03 |
原启生物科技(上海)有限责任公司 |
靶向tigit的抗原结合蛋白及其用途
|
|
KR20240156411A
(ko)
|
2022-03-09 |
2024-10-29 |
브리스톨-마이어스 스큅 컴퍼니 |
치료 단백질의 일시적 발현
|
|
AU2023236289A1
(en)
|
2022-03-15 |
2024-08-15 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
|
CA3250812A1
(en)
*
|
2022-04-29 |
2023-11-02 |
Merck Sharp & Dohme Llc |
Stable formulations of anti-ILT4 antibodies or antigen-binding fragments thereof in combination with anti-PD-1 antibodies and their methods of use
|
|
IL317449A
(en)
|
2022-06-07 |
2025-02-01 |
Genentech Inc |
Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
|
|
WO2024003360A1
(en)
|
2022-07-01 |
2024-01-04 |
Institut Curie |
Biomarkers and uses thereof for the treatment of neuroblastoma
|
|
EP4565610A1
(en)
|
2022-08-02 |
2025-06-11 |
Ose Immunotherapeutics |
Multifunctional molecule directed against cd28
|
|
CN120202220A
(zh)
*
|
2022-08-26 |
2025-06-24 |
南京传奇生物科技有限公司 |
靶向tigit的抗体及其用途
|
|
JP2026510747A
(ja)
|
2023-03-15 |
2026-04-10 |
シャンハイ マブジェン バイオテック リミテッド |
Ｐｄ－１／ｐｖｒｉｇ／ｔｉｇｉｔ結合タンパク質を含む医薬組成物及びその医薬的使用
|
|
EP4687990A1
(en)
|
2023-03-30 |
2026-02-11 |
Ose Immunotherapeutics |
Method of synthesis of targeted lipid nanoparticle and uses thereof
|
|
JP2026512425A
(ja)
|
2023-03-30 |
2026-04-16 |
オーエスイー・イミュノセラピューティクス |
免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025068461A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025068452A1
(en)
|
2023-09-29 |
2025-04-03 |
Negio Therapeutics |
Guanfacine derivatives and their use in treating cancer
|
|
WO2025132831A1
(en)
|
2023-12-19 |
2025-06-26 |
Universite D'aix-Marseille |
N-heteroaryl derivatives and uses thereof for treating cancer
|
|
WO2025242836A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
|
|
WO2025242835A1
(en)
|
2024-05-22 |
2025-11-27 |
Ose Immunotherapeutics |
Molecules comprising masking linkers and uses thereof for the treatment of cancer
|
|
WO2025262250A1
(en)
|
2024-06-20 |
2025-12-26 |
Negio Therapeutics |
Guanfacine derivatives and their uses
|
|
WO2026068705A1
(en)
|
2024-09-26 |
2026-04-02 |
Ose Immunotherapeutics |
Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof
|